BBC:NYE-Virtus LifeSci Biotech Clinical Trials ETF (USD)

ETF | Health |

Last Closing

USD 27.9405

Change

+0.06 (+0.20)%

Market Cap

USD 0.01B

Volume

1.55K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B

ETFs Containing BBC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.27% 93% A 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.27% 83% B 61% D-
Trailing 12 Months  
Capital Gain 48.34% 98% N/A 89% A-
Dividend Return 0.44% 36% F 5% F
Total Return 48.78% 98% N/A 88% B+
Trailing 5 Years  
Capital Gain 18.61% 7% C- 55% F
Dividend Return 0.35% 19% F 2% F
Total Return 18.96% 7% C- 44% F
Average Annual (5 Year Horizon)  
Capital Gain -1.41% N/A N/A 29% F
Dividend Return -1.35% N/A N/A 17% F
Total Return 0.06% N/A N/A 2% F
Risk Return Profile  
Volatility (Standard Deviation) 36.05% N/A N/A 27% F
Risk Adjusted Return -3.74% N/A N/A 22% F
Market Capitalization 0.01B 5% F 8% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.